Background: Direct antiglobulin test (DAT)-negative warm autoimmune hemolytic anemia (AIHA) is mainly caused by three mechanisms: red blood cell (RBC)-bound immunoglobulin (Ig)G below the detection limit of routine DAT; RBC-bound IgA or IgM; or low-affinity autoantibodies. Although most cases of DAT-negative AIHA are thought to be caused by RBC-bound IgG, and combinatory serological analyses are recommended, the relative ratios of each mechanism have not been clarified. Methods: Two groups of patients with undiagnosed hemolytic anemia and negative conventional tube method-DAT (TM-DAT) were investigated using anti-IgA and anti-IgM sera, or column agglutination method-DAT (CM-DAT), respectively, in addition to radioimmunological quantitation of RBC-bound IgG. Results: Three of 73 patients with DAT-negative AIHA showed positive RBC-bound IgA and normal amounts of RBC-bound IgG. Another group of 3 patients were RBC-bound IgM-positive, but only one of these showed normal amounts of RBC-bound IgG. In another group of patients with DAT-negative AIHA, 4 of the 20 showed positive CM-DAT and negative CM-DAT after washing RBCs. Three of these patients had normal amounts of RBC-bound IgG. Five patients with positive CM-DAT both before and after washing RBCs had high amounts of RBC-bound IgG. Conclusion: Relative ratios of patients with DAT-negative AIHA resulting from RBC-bound IgG, RBC-bound IgA, RBC-bound IgM, and low-affinity IgG were estimated as 80, 4, 1 and 15%, respectively. A new classification and diagnostic algorithm for DAT-negative AIHA were proposed.

Keywords:
Autoimmune hemolytic anemia, Direct antiglobulin test, IgA/M, Low-affinity IgG, Diagnostic algorithm
1.
Petz LD, Garratty G: Immune Hemolytic Anemias (ed 2). Philadelphia, Churchill Livingstone, 2004.
2.
Engelfriet CP, Overbeeke MA, von dem Borne AE: Autoimmune hemolytic anemia. Semin Hematol 1992; 29: 3–12.
3.
Evans RS, Weiser RS: The serology of autoimmune hemolytic disease; observations on forty-one patients. AMA Arch Intern Med 1957; 100: 371–399.
4.
Worlledge SM, Blajchman MA: The autoimmune haemolytic anaemias. Br J Haematol 1972; 23: 61–69.
5.
Chaplin H Jr: Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias. Prog Hematol 1973; 8: 25–49.
6.
Issitt PD, Gutgseu NS: Clinically significant antibodies not detected by routine methods; in Nance S (ed): Immune Destruction of Red Blood Cells. Arlington, American Association of Blood Banks 1989, pp 93–99.
7.
Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E: Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol 2009; 84: 98–101.
8.
Garratty G: Immune hemolytic anemia associated with negative routine serology. Semin Hematol 2005; 42: 156–164.
9.
Jeje MO, Blajchman MA, Steeves K, Horsewood P, Kelton JG: Quantitation of red cell-associated IgG using an immunoradiometric assay. Transfusion 1984; 24: 473–476.
10.
Omine M, Kajii E, Kamesaki T, Karasawa M: A reference guide for diagnosis and treatment of autoimmunne hemolytic anemia. Jpn J Clin Hematol 2006; 47: 117–136.
11.
Sugano N, Obata T, Onozaki F, et al: Hemagglutination reaction by column agglutination: comparison of the conventional tube, bead and gel techniques. Jpn J Med Technol 2000; 49: 951–955.
12.
Kamesaki T, Toyotsuji T, Kajii E: Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: a study of 154 cases. Am J Hematol 2013; 88: 93–96.
13.
Segel GB, Lichtman MA: Direct antiglobulin (“Coombs”) test-negative autoimmune hemolytic anemia: a review. Blood Cells Mol Dis 2014; 52: 152–160.
14.
Leger RM, Co A, Hunt P, Garrity G: Attempts to support an immune etiology in 800 patients with direct antiglobulin test-negative hemolytic anemia. Immunohematology 2010; 26: 156–160.
15.
Lai M, Rumi C, D’Onofrio G, Voso MT, -Leone G: Clinically significant autoimmune hemolytic anemia with a negative -direct antiglobulin test by routine tube test and positive by column agglutination method. Immunohematology 2002; 18: 109–113.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.